- Home
- HPP vs ERAS Comparison
HPP vs ERAS Comparison
Compare HPP & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- ERAS
- Stock Information
- Founded
- HPP 1997
- ERAS 2018
- Country
- HPP United States
- ERAS United States
- Employees
- HPP N/A
- ERAS N/A
- Industry
- HPP Real Estate
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- ERAS Health Care
- Exchange
- HPP Nasdaq
- ERAS Nasdaq
- Market Cap
- HPP 319.5M
- ERAS 348.4M
- IPO Year
- HPP 2010
- ERAS 2021
- Fundamental
- Price
- HPP $2.75
- ERAS $1.54
- Analyst Decision
- HPP Hold
- ERAS Strong Buy
- Analyst Count
- HPP 11
- ERAS 6
- Target Price
- HPP $3.09
- ERAS $4.83
- AVG Volume (30 Days)
- HPP 15.8M
- ERAS 1.2M
- Earning Date
- HPP 08-05-2025
- ERAS 08-11-2025
- Dividend Yield
- HPP N/A
- ERAS N/A
- EPS Growth
- HPP N/A
- ERAS N/A
- EPS
- HPP N/A
- ERAS N/A
- Revenue
- HPP $818,699,000.00
- ERAS N/A
- Revenue This Year
- HPP N/A
- ERAS N/A
- Revenue Next Year
- HPP $4.66
- ERAS N/A
- P/E Ratio
- HPP N/A
- ERAS N/A
- Revenue Growth
- HPP N/A
- ERAS N/A
- 52 Week Low
- HPP $1.78
- ERAS $1.01
- 52 Week High
- HPP $6.29
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- HPP 64.07
- ERAS 58.61
- Support Level
- HPP $2.67
- ERAS $1.38
- Resistance Level
- HPP $2.80
- ERAS $1.49
- Average True Range (ATR)
- HPP 0.12
- ERAS 0.11
- MACD
- HPP -0.02
- ERAS 0.01
- Stochastic Oscillator
- HPP 51.52
- ERAS 96.97
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.